Genflow Biosciences plc Share Price

Equities

GENF

GB00BP2C3V08

Biotechnology & Medical Research

Market Closed - London S.E. 07:30:00 01/05/2024 BST 5-day change 1st Jan Change
2.05 GBX 0.00% Intraday chart for Genflow Biosciences plc +15.49% +43.86%
Sales 2021 - Sales 2022 - Capitalization 7.02M 560M
Net income 2021 - 0 Net income 2022 -1M -79.71M EV / Sales 2021 * -
Net cash position 2021 254K 20.27M Net cash position 2022 2.36M 188M EV / Sales 2022 -
P/E ratio 2021 *
-
P/E ratio 2022
-5.26 x
Employees 5
Yield 2021 *
-
Yield 2022
-
Free-Float 36.34%
More Fundamentals * Assessed data
Dynamic Chart
1 week+15.49%
1 month+39.46%
3 months+26.15%
6 months+32.26%
Current year+43.86%
More quotes
1 week
1.85
Extreme 1.85
2.20
1 month
1.40
Extreme 1.4
2.20
Current year
1.32
Extreme 1.3225
2.28
1 year
1.32
Extreme 1.3225
3.90
3 years
1.32
Extreme 1.3225
13.50
5 years
1.32
Extreme 1.3225
13.50
10 years
1.32
Extreme 1.3225
13.50
More quotes
Managers TitleAgeSince
Founder 66 31/12/19
Members of the board TitleAgeSince
Director/Board Member 64 28/06/22
Chairman 61 28/06/22
Founder 66 31/12/19
More insiders
Date Price Change Volume
01/05/24 2.05 0.00% 0
30/04/24 2.05 +2.50% 2,240,725
29/04/24 2 +12.68% 4,712,023
26/04/24 1.775 +9.23% 1,412,621

Delayed Quote London S.E., May 01, 2024 at 07:30 am

More quotes
Genflow Biosciences Plc is a United Kingdom-based biotechnology company. The Company is engaged in developing gene therapies designed to target the aging process and to reduce and delay the incidence of age-related diseases, which is done through therapeutics targeting aging in humans by using adeno-associated virus (AAV) vectors to deliver copies of the Sirtuin-6 (SIRT6) gene variant that is found in centenarians into cells. The Company's product line includes GF-1002, GF-3001 and GF-4001. GF-4001. GF-1002 is a suspension of an adeno-associated viral vector-based gene therapy for intravenous infusion. GF-4001 is a non-human version of GF-1002 anti-ageing gene therapy developed for veterinary use (dogs). GF-3001 is a formulation of an adeno-associated viral vector-based gene therapy. The Company has operations in the United Kingdom and Belgium.
More about the company